Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MGC Pharmaceuticals Ltd reported an increased loss and and a lower revenue in the financial year that ended on June 30.
MGC Pharmaceuticals is a pharmaceutical company specialising in the production and development of plant-derived medicines.
The company said annual pretax loss widened to A$21.1 million from A$20.8 million a year prior. Cost of sales decreased 33% to A$1.9 million from A$2.9 million. However, revenue declined 28% to A$3.4 million from A$4.7 million. Further, administrative expenses increased 26% to A$14.9 million from A$11.8 million.
On a positive note, MGC Pharma reported a fair value movement gain on financial instruments of A$86,636, compared to a loss of A$1.2 million a year ago.
The company highlighted that during the year, it received permission from the Slovenian Ministry of Health to undergo scientific research development on the psychedelic compound psilocybin. It aims to develop and research psilocybin-based medicines.
MGC Pharmaceuticals shares closed 3.7% lower at 0.13 pence each on Thursday in London.
Copyright 2023 Alliance News Ltd. All Rights Reserved.